Volume 9 , Issue 3 , September 2021 , Pages: 171 - 175
A Phase 1 Dose Escalation Study of Eribulin in Combination with Weekly Carboplatin for the Treatment of Metastatic Breast Cancer
Aixa Elena Soyano, Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
Michael Shafique, Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
Roohi Ismail-Khan, Satellite and Community Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
Dawn Goodridge, Department of Late Phase Research, Florida Cancer Specialists & Research Institute, Tampa, USA
David Boulware, Department of Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
Hatem Soliman, Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
Hyo Sook Han, Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
Received: Aug. 2, 2021;       Accepted: Aug. 24, 2021;       Published: Aug. 31, 2021
DOI: 10.11648/j.crj.20210903.17        View        Downloads  
Background: Metastatic breast cancer is a common and devastating diagnosis. New strategies for treatment are needed to help improve outcomes. Eribulin is an anti-microtubule agent approved in 2010 for advanced breast cancer. Combination with other chemotherapeutic agents provides an alternative treatment option for these patients. Purpose: This study evaluates the safety, tolerability and activity of eribulin and weekly carboplatin in a dose-escalation schema in patients with metastatic breast cancer. Methods: Patients were treated with eribulin and carboplatin AUC 2 administered on the first and eighth days of a 21-day cycle. Three doses of eribulin (0.9, 1.1 and 1.4 mg/m2) were examined. An additional 10 patients were enrolled into an expansion cohort at the recommended Phase 2 dose. Results: A total of 19 patients were treated, including 10 patients in the dose expansion cohort. There was no dose limiting toxicity related to the study therapy in the dose escalation cohorts. Grade 3 toxicities included neutropenia (21%), anemia (10%), fatigue (10%), peripheral sensory neuropathy (10%), infusion related reactions (5%), pericardial effusion (5%), diarrhea (5%) and pleural effusion (5%). Twenty-six percent of patients had grade 4 neutropenia, but there were no events of sepsis or febrile neutropenia. The maximum tolerated dose (MTD) of eribulin in combination with carboplatin AUC 2 was determined to be 1.4 mg/m2. Four patients experienced clinical benefit, 2 patients with stable disease greater than 6 months and 2 patients with partial response, demonstrating a clinical benefit rate of 21%. Conclusion: Eribulin and weekly carboplatin appeared to be safe and well tolerated with demonstrated clinical benefit. The recommended Phase 2 dose level was 1.4 mg/m2 of eribulin. Further studies can be pursued for this combination regimen to establish its efficacy.
Eribulin, Breast Neoplasms, Drug Therapy, Breast Cancer
To cite this article
Aixa Elena Soyano, Michael Shafique, Roohi Ismail-Khan, Dawn Goodridge, David Boulware, Hatem Soliman, Hyo Sook Han, A Phase 1 Dose Escalation Study of Eribulin in Combination with Weekly Carboplatin for the Treatment of Metastatic Breast Cancer, Cancer Research Journal. Vol. 9, No. 3, 2021, pp. 171-175. doi: 10.11648/j.crj.20210903.17
Copyright © 2021 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
[ 1 ]
Siegel RL, Miller KD, Fuchs HE, Jemal A: Cancer Statistics, 2021. CA Cancer J Clin 2021, 71(1):7-33.
[ 2 ]
Cancer Stat Facts: Female Breast Cancer [https://seer.cancer.gov/statfacts/html/breast.html]
[ 3 ]
Chia SK, Speers CH, D'Yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O'Reilly S E, Olivotto IA: The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007, 110 (5): 973-979.
[ 4 ]
O'Shaughnessy J: Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005, 10 Suppl 3: 20-29.
[ 5 ]
Zeichner SB, Herna S, Mani A, Ambros T, Montero AJ, Mahtani RL, Ahn ER, Vogel CL: Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature. Breast Cancer Res Treat 2015, 153 (3): 617-624.
[ 6 ]
Moreno-Aspitia A, Perez EA: Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc 2009, 84 (6): 533-545.
[ 7 ]
Halaven (eribulin) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; February 2021
[ 8 ]
Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E: Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 1991, 266 (24): 15882-15889.
[ 9 ]
Hirata Y, Uemura D: Halichondrins-antitumor polyether macrolides from a marine sponge. Pure and Applied Chemistry 1986, 58 (5): 701-710.
[ 10 ]
Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA: Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004, 64 (16): 5760-5766.
[ 11 ]
Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA: Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 2008, 7 (7): 2003-2011.
[ 12 ]
Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, Jordan MA: Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 2010, 49 (6): 1331-1337.
[ 13 ]
Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA: Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 2010, 10 (2): 160-163.
[ 14 ]
Swami U, Petrylak DP, Raftopoulos H, Shuster DE, Wang G, Kumar V, Martinez G, Goel S, Aisner J: Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol 2010, 28 (15): 2589.
[ 15 ]
Romano PM, Baraibar I, Fernandez-Hidalgo O, Santisteban M, Espinos J, Salas D, Sala P, Gardeazabal I, Oteiza LZ, Aramendia JM: Eribulin and carboplatin in heavily pretreated patients with metastatic breast cancer: A single institution experience. J Clin Oncol 2015, 33 (28): 122.
[ 16 ]
Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms KM, Gutin A, Abkevich V, Sangale Z, Solimeno C, Brown KL et al: Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579). Breast Cancer Res Treat 2015, 151 (3): 629-638.
[ 17 ]
Loesch D, Robert N, Asmar L, Gregurich MA, O'Rourke M, Dakhil S, Cox E: Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol 2002, 20 (18): 3857-3864.
[ 18 ]
Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T et al: Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011, 377 (9769): 914-923.
[ 19 ]
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45 (2): 228-247.
Browse Journals by Subject